Nationwide Fund Advisors boosted its stake in PAREXEL International Corporation (NASDAQ:PRXL) by 0.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 249,462 shares of the medical research company’s stock after purchasing an additional 591 shares during the period. Nationwide Fund Advisors owned about 0.49% of PAREXEL International Corporation worth $21,681,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in PRXL. Capstone Asset Management Co. increased its stake in PAREXEL International Corporation by 3.8% in the 1st quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock worth $278,000 after purchasing an additional 160 shares during the period. First Trust Advisors LP increased its stake in PAREXEL International Corporation by 216.7% in the 1st quarter. First Trust Advisors LP now owns 29,536 shares of the medical research company’s stock worth $1,864,000 after purchasing an additional 20,210 shares during the period. Swiss National Bank increased its stake in PAREXEL International Corporation by 1.0% in the 1st quarter. Swiss National Bank now owns 87,800 shares of the medical research company’s stock worth $5,541,000 after purchasing an additional 900 shares during the period. Gabelli Funds LLC purchased a new position in PAREXEL International Corporation in the 1st quarter worth approximately $1,136,000. Finally, Meadow Creek Investment Management LLC increased its stake in PAREXEL International Corporation by 7.1% in the 1st quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock worth $125,000 after purchasing an additional 132 shares during the period. 87.45% of the stock is currently owned by institutional investors and hedge funds.
Shares of PAREXEL International Corporation (NASDAQ PRXL) opened at 87.95 on Monday. PAREXEL International Corporation has a 52-week low of $51.16 and a 52-week high of $87.98. The company has a market capitalization of $4.50 billion, a price-to-earnings ratio of 42.69 and a beta of 0.79. The company’s 50 day moving average price is $87.71 and its 200 day moving average price is $77.62.
PAREXEL International Corporation (NASDAQ:PRXL) last released its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to the consensus estimate of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same period last year, the business posted $0.94 EPS. On average, analysts predict that PAREXEL International Corporation will post $3.95 EPS for the current year.
WARNING: This story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/18/nationwide-fund-advisors-has-21-68-million-holdings-in-parexel-international-corporation-prxl.html.
A number of brokerages have commented on PRXL. Zacks Investment Research cut PAREXEL International Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. BidaskClub cut PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research note on Tuesday, June 20th. Jefferies Group LLC reissued a “hold” rating and set a $88.10 target price on shares of PAREXEL International Corporation in a research note on Wednesday, June 21st. Finally, Mizuho boosted their target price on PAREXEL International Corporation from $66.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, May 30th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $75.92.
About PAREXEL International Corporation
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).
Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.